国立研究開発法人量子科学技術研究開発機構量子医学・医療部門放射線医学総合研究所先進核医学基盤研究部放射性核種製造グループTargetry and Target Chemistry Group, Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology
学術雑誌のオンライン検索を利用して，核医学で利用されるRIの種類や頻度の俯瞰を試みた。最近10年において研究利用されるRIの多くは，ポジトロン放出核種や治療用のβ核種であり，診断と治療，すなわち，セラノスティクスを具現化するRI利用が進展している傾向を得た。また，α核種の利用はこの10年間における大きな変化の一つであり，核医学における新たな賦活剤として，今後の利用とそれに伴う成果報告の増加が期待される。
This report describes an overview of the radioisotopes used in nuclear medicine. The statistic information on the frequency was acquired via an online survey provided by the Journal of Nuclear Medicine. In this decade, most frequent workhorses of radioisotope are found to be positron-emitters for PET diagnostic tests, as well as beta-emitters for therapeutic application. These results suggest that ‘theranostics’ in nuclear medicine has already been widely accepted as the mainstream of medical treatment and the evidence for the applicable way of radioactive materials. In addition, targeted alpha therapy (TAT), an emerging therapy with appropriate alpha-emitters appeared in this decade, gives the highest impact to our community. The TAT has great potential to stimulate our research activities, as well as to enhance the following clinical achievements.
Key words: targeted radionuclide therapy (TRT); targeted alpha therapy (TAT); radioisotope; nuclear medicine; emerging radionuclide; theranostics; alpha-emitter
© 2020 公益社団法人日本アイソトープ協会© 2020 Japan Radioisotope Association
This page was created on 2020-02-21T17:20:45.283+09:00
This page was last modified on 2020-04-27T15:13:46.000+09:00
このサイトは（株）国際文献社によって運用されています。
